AIM
WHWK

Alambic Investment Management’s Whitehawk Therapeutics WHWK Stock Holding History

Alambic Investment Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,351
Closed -$24K – 360
2019
Q3 		$24K Sell
2,351
-967
-29% -$10.7K 0.02% 296
2019
Q2 		$45K Sell
3,318
-2,982
-47% -$45.2K 0.03% 285
2019
Q1 		$85K Buy
+6,300
New +$271K 0.03% 324

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JIC
Johnson Investment Counsel Cincinnati, Ohio $13.7B AUM 21.52% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Alambic Investment Management's WHWK Position: Q4 2019 in Review

Alambic Investment Management sold out of Whitehawk Therapeutics (WHWK) in Q4 2019, closing a stake of 2,351 shares — an estimated $24K sold.

Alambic Investment Management first reported a position in WHWK in Q1 2019 and held it in 3 quarters. The position peaked at $85K in Q1 2019. 22 funds tracked by Wall St. Rank hold WHWK as of Q4 2019.

  • Alambic Investment Management reported no remaining Whitehawk Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Alambic Investment Management sold 2,351 Whitehawk Therapeutics shares in Q4 2019, an estimated $24K.
  • Alambic Investment Management first reported a position in Whitehawk Therapeutics in Q1 2019 and held it in 3 quarters.
  • Alambic Investment Management's Whitehawk Therapeutics position peaked at $85K in Q1 2019.
  • 22 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2019.

Based on Alambic Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.